AlphaMadera's AlphaVal page computes Williams-Sonoma, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag WSM as undervalued, fairly valued, or overvalued.

What is Williams-Sonoma, Inc.'s fair value?

Fair value for WSM is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value WSM?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from WSM's most recent reported fundamentals.

WSM - Williams-Sonoma, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $201.17 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 18.6% above fair value

Current Price $192.50

Bear Case $142.05 26.2% downside ($142.05 - $192.50) / $192.50 = -26.2% $8.84 × 14x P/E

Fair Value $162.35 15.7% downside ($162.35 - $192.50) / $192.50 = -15.7% $8.84 × 16x P/E

Bull Case $182.64 5.1% downside ($182.64 - $192.50) / $192.50 = -5.1% $8.84 × 18x P/E

Adjust Assumptions

P/E Multiple

16.0x

Adjusted EPS

8.84$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 21.8x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $201.17 from 56 analysts, using a 35% weight on analyst consensus. That produces an estimated intrinsic value of $162.35 per share.

Warnings

ℹ Wall Street's average price target is $201.17 (from 56 analysts). Our estimate is 30% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples